U.S. stock market midday update: Danaher rises 7.33%, raises earnings guidance and acquires Masimo to boost confidence

U.S. Stock Market Midday Update

Danaher rose 7.33%. Based on recent news,

1. On July 21, Danaher raised its full-year earnings guidance due to better-than-expected second-quarter performance. The company expects adjusted earnings per share for 2026 to be between $8.45 and $8.60, up from the previous forecast of $8.35 to $8.55. This news boosted market confidence and drove the stock price up.

2. On July 21, Danaher completed its acquisition of health technology company Masimo, which is expected to immediately enhance adjusted earnings per share. This move further strengthened investor expectations for the company's future growth, pushing the stock price higher.

3. On July 21, although Danaher lowered the upper limit of its revenue growth forecast for 2026, the life sciences business performed strongly, with core sales growth of 3% in the second quarter. All three business segments recorded growth, particularly the life sciences segment, which achieved its strongest quarterly performance in years. These positive factors collectively drove the stock price up. The life sciences industry is recovering, and market confidence is increasing.

Top Stocks by Industry Trading Volume

Thermo Fisher Scientific rose 8.97%. Based on recent news,

1. On July 23, Thermo Fisher Scientific reported growth in both revenue and profit for the second fiscal quarter. The company achieved a profit of $1.74 billion, with earnings per share of $4.68, and adjusted earnings per share of $6.03, exceeding analysts' expectations of $5.72. Revenue grew by 10% to $11.99 billion, surpassing analysts' forecast of $11.71 billion. This reflects strong performance in the end markets and an increase in market share.

2. On July 23, Thermo Fisher Scientific raised its full-year revenue guidance for 2026 to between $47.4 billion and $48.1 billion, expecting an overall revenue growth of about 4%. The company stated that it expects to reach the upper limit of the guidance range.

3. On July 23, Thermo Fisher Scientific opened a bioprocess design center in Massachusetts to expand its business footprint and support more drug development and production. The overall healthcare technology sector is recovering, and market confidence is increasing.

Medpace Holdings rose 15.23%. Based on recent key news:

1. On July 22, Medpace released its second-quarter financial report, with net income reaching $121.362 million, a year-on-year increase of 34.5%. This strong financial performance drove the stock price up. Source: Reuters

2. On July 23, Medpace raised its earnings and revenue guidance for the fiscal year 2026, expecting earnings per share to be between $17.25 and $17.95, and revenue to be between $2.805 billion and $2.885 billion. The market is optimistic about the company's future growth, leading to an increase in stock price. Source: Benzinga

3. On July 23, analysts maintained a neutral rating on Medpace, despite the company's strong performance, as they remain cautious about the sustainability of booking growth. Source: Truist Securities The biotechnology sector has recently performed strongly, with significant capital inflows West Pharmaceutical Services fell 0.70%. Based on recent key news:

4. On July 23, West Pharmaceutical Services announced a second-quarter net sales of $872.3 million, exceeding market expectations. The company raised its full-year net sales and earnings per share guidance, driving stock price fluctuations. Source: Reuters

5. On July 23, the company anticipated strong growth in high-value product components and biopharmaceuticals to drive full-year performance. Despite facing cost pressures, the company still raised its performance guidance. Source: Benzinga

6. On July 22, West Pharmaceutical Services announced a quarterly dividend distribution, causing stock price fluctuations. Source: Public Technologies The pharmaceutical industry is experiencing strong growth, with cost pressures emerging.

Stocks ranked among the top in industry market capitalization

Agilent Technologies rose 4.00%. Based on recent key news:

1. On July 23, Agilent received EU certification for its PD-L1 IHC 22C3 pharmDx companion diagnostic for certain ovarian-related cancers. This label expansion supports Merck's KEYTRUDA use in the EU, driving stock price up.

2. On July 22, Agilent announced that its BDR program in Brazil would adjust the ratio of underlying shares to BDRs from 1:2 to 1:10, with a mandatory stock split providing an additional 4 BDRs for each shareholder holding 1 BDR, enhancing market confidence.

3. On July 21, Agilent reported a second-quarter revenue growth of 5.5% to $6.27 billion, exceeding expectations, with life sciences revenue growing 5.5% to $1.88 billion, boosting investor sentiment. The technology sector continues to grow, attracting investor attention